Program to optimize the treatment compliance and blood pressure control in hypertensive patients in real cardiologist's practice

Open clinical program implemented to optimize efficacy of blood pressure control and patient's compliance in every day out-patient cardiological practice

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN75706523

Enrollment

520

Registered

2013-05-23

Start date

2012-03-10

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial hypertension Circulatory System Hypertension

Interventions

If the patient previously was not treated, he is administered fixed combination of perindopril/amlodipine (Bi-Prestarium) in dose of 5/5 mg, 5/10 or 10/5 mg once per day. The doctor chooses the dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient with arterial hypertension 2. Men and women aged 35-70 years 3. Not yet treated with BP>160/100 140/90 140/90 140/90 <200/120 mm Hg) *patients should stop previous treatment at the day of inclusion and be switched to fixed combination of perindopril arginine/amlodipine ?-blocker allowed for CAD patients but dose of ?-blockers should be stable during all period of study.

Exclusion criteria

Exclusion criteria: 1. Cerebrovascular events within 3 last month of anamnesis 2. Myocardial infarction within 6 last of anamnesis 3. Valvular heart disease 4. Uncontrolled arrhythmias 5. Pregnant or lactating woman 6. COPD during exasperation 7. Contraindications linked to ACEi or CCBs, or its intolerance (including allergic reaction linked to these drugs) 8. II types diabetes ( fasting glycaemia>7 mmol/l) 9. Renal failure (GFR200/120 mm Hg

Design outcomes

Primary

Measure	Time frame
1. Percentage of the patients who had achieved BP (less than 140/90 mm Hg) and for diabetes pts . BP<135/85 mm Hg 2. Percentage of the patients who had achieved home BP (less than 135/85 mm Hg)	—

Secondary

Measure	Time frame
1.Compare the achievement of target office blood pressure with a frequency achievement of target home BP, according to an independent measurement of blood pressure 2. Frequency of achieving BP control (<135/80 mm Hg.) for self-measurement of home blood pressure 3. Dynamics of office SBP and DBP reduction 4. Assessment of tolerability: dynamics of the patient's side effect 5. Assessment of adherence: Dynamics of the patient`s compliance - patient compliance assessed by questionnaire test X. Girerd Sub study 1.Dynamic of average daytime and nighttime SBP and DBP assessed with ABPM 2. Dynamics of central systolic blood pressure and central pulse pressure dynamics 3. Dynamic of echocardiography indexes 4. Dynamics of pulse wave velocity	—

Measure

Time frame

1.Compare the achievement of target office blood pressure with a frequency achievement of target home BP, according to an independent measurement of blood pressure 2. Frequency of achieving BP control (<135/80 mm Hg.) for self-measurement of home blood pressure 3. Dynamics of office SBP and DBP reduction 4. Assessment of tolerability: dynamics of the patient's side effect 5. Assessment of adherence: Dynamics of the patient`s compliance - patient compliance assessed by questionnaire test X. Girerd Sub study 1.Dynamic of average daytime and nighttime SBP and DBP assessed with ABPM 2. Dynamics of central systolic blood pressure and central pulse pressure dynamics 3. Dynamic of echocardiography indexes 4. Dynamics of pulse wave velocity

—

Countries

Ukraine

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 4, 2026